| __timestamp | Bio-Techne Corporation | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 17268000 |
| Thursday, January 1, 2015 | 119401000 | 19667000 |
| Friday, January 1, 2016 | 140879000 | 27823000 |
| Sunday, January 1, 2017 | 199243000 | 36468000 |
| Monday, January 1, 2018 | 240636000 | 31282000 |
| Tuesday, January 1, 2019 | 264359000 | 39610000 |
| Wednesday, January 1, 2020 | 260583000 | 52820000 |
| Friday, January 1, 2021 | 324951000 | 96803000 |
| Saturday, January 1, 2022 | 372766000 | 177977000 |
| Sunday, January 1, 2023 | 378378000 | 173612000 |
| Monday, January 1, 2024 | 396826000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, operational efficiency is key to sustaining growth and innovation. Over the past decade, Bio-Techne Corporation and Cytokinetics, Incorporated have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Bio-Techne's SG&A expenses have surged by over 550% from 2014 to 2023, reflecting its aggressive expansion and strategic investments. In contrast, Cytokinetics has seen a more modest increase of approximately 900% during the same period, indicating a more cautious approach to scaling operations.
The year 2022 marked a pivotal point for Cytokinetics, with SG&A expenses peaking at nearly 180% of their 2021 levels, suggesting a significant shift in their operational strategy. Meanwhile, Bio-Techne's consistent growth in SG&A expenses underscores its commitment to maintaining a robust operational framework. As we look to the future, these trends offer valuable insights into the strategic priorities of these biotech leaders.
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Alnylam Pharmaceuticals, Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Biogen Inc. and Bio-Techne Corporation
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Cytokinetics, Incorporated
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Bio-Techne Corporation and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Vericel Corporation
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.